Cyramza, with the generic name Ramucirumab, is a medication used in the treatment of certain types of cancer. It belongs to a class of drugs known as vascular endothelial growth factor (VEGF) receptor antagonists. Here is a detailed description:

1. Mechanism of Action:

• VEGF Receptor Antagonist: Ramucirumab is a monoclonal antibody that specifically targets and inhibits the vascular endothelial growth factor (VEGF) receptor, thereby reducing the growth and development of blood vessels that supply tumors.

2. Indications:

• Gastric Cancer: Cyramza is indicated for the treatment of advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, either as a single agent or in combination with other chemotherapy drugs.
• Non-Small Cell Lung Cancer (NSCLC): It is also approved for use in combination with docetaxel for the treatment of metastatic NSCLC with disease progression on or after platinum-based chemotherapy.

3. Administration:

• Intravenous Infusion: Cyramza is administered as an intravenous infusion, typically over a specified period under the supervision of a healthcare professional.

4. Dosage:

• The dosage of Ramucirumab may vary based on the specific indication and the patient’s individual characteristics. The standard dosage is often 8 mg/kg administered every two weeks.

5. Effectiveness:

• Clinical studies have demonstrated that Cyramza, when used either alone or in combination with other agents, can improve overall survival and progression-free survival in patients with advanced gastric cancer or metastatic NSCLC.

6. Safety Profile:

• Common side effects may include hypertension, fatigue, diarrhea, and decreased appetite. Serious side effects, such as bleeding or blood clotting disorders, may occur and require close monitoring.

7. Monitoring:

• Patients receiving Cyramza may undergo regular monitoring of blood pressure and laboratory parameters to assess the response to treatment and detect any potential side effects.

8. Contraindications:

• Cyramza is generally contraindicated in individuals with severe hypersensitivity reactions to Ramucirumab or any of its components.

9. Precautions:

• Due to the risk of bleeding, caution is advised in patients with a history of bleeding disorders or those taking anticoagulant medications.

10. Follow-Up Care:

• Patients receiving Cyramza will likely undergo follow-up care to assess treatment response, manage side effects, and make any necessary adjustments to the treatment plan.

Cyramza (Ramucirumab) is an important treatment option for certain advanced cancers, offering therapeutic benefits by targeting specific pathways involved in tumor growth. As with any cancer therapy, treatment decisions should be made in consultation with a qualified oncologist, taking into account the individual patient’s health status and the specific characteristics of the cancer being treated.